Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Enterprise Value: 2012-2024

Historic Enterprise Value for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $1.6 billion.

  • Amphastar Pharmaceuticals' Enterprise Value fell 54.40% to $962.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.6 million, marking a year-over-year decrease of 79.77%. This contributed to the annual value of $1.6 billion for FY2024, which is 42.22% down from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Enterprise Value stood at $1.6 billion for FY2024, which was down 42.22% from $2.7 billion recorded in FY2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Enterprise Value peaked at $2.7 billion during FY2023, and registered a low of $896.1 million during FY2020.
  • Its 3-year average for Enterprise Value is $1.8 billion, with a median of $1.6 billion in 2024.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Enterprise Value skyrocketed by 129.64% in 2023, and later crashed by 42.22% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Enterprise Value (Yearly) stood at $896.1 million in 2020, then climbed by 9.11% to $977.7 million in 2021, then rose by 20.53% to $1.2 billion in 2022, then soared by 129.64% to $2.7 billion in 2023, then plummeted by 42.22% to $1.6 billion in 2024.